April 16, 2024

Antiparasitic Drugs Market Size to Attain USD 30.42 Bn by 2033

The antiparasitic drugs market size is poised to grow by USD 30.42 billion by 2033 from USD 18.50 billion in 2023, exhibiting a CAGR of 5.10% during the forecast period 2024-2033.

Antiparasitic Drugs Market Size 2024 to 2033

Key Points

  • North America dominated the market with the largest market share of 37% in 2023.
  • Asia Pacific is expected to witness the fastest expansion rate in the antiparasitic drugs market during the forecast period.
  • By drug type, the anthelmintics drug segment dominated the market in 2023.
  • By drug type, the antiprotozoal drug segment is expected to grow at the fastest rate during the forecast period.
  • By route of administration, the injectable segment held the largest share of the market in 2023.
  • By distribution channel, the hospital pharmacies segment dominated the market in 2023.
  • By distribution channel, the retail pharmacies segment is expected to witness the fastest growth rate during the forecast period.

Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Antiparasitic drugs market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.

To begin with, the Antiparasitic drugs Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.

Get a Sample Reporthttps://www.precedenceresearch.com/sample/3822

Antiparasitic Drugs Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 5.10%
Global Market Size in 2023 USD 18.50 Billion
Global Market Size by 2033 USD 30.42 Billion
U.S. Market Size in 2023 USD 4.79 Billion
U.S. Market Size by 2033 USD 7.88 Billion
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Drug Type, By Route of Administration, and By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read More: Diaphragm Pumps Market Size to Hit USD 11.65 Bn by 2033

The empirical study on the global Antiparasitic drugs market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Antiparasitic drugs Market. Our market report for the Antiparasitic drugs market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.

Antiparasitic Drugs Market Companies

  • GlaxoSmithKline plc
  • Merck KGaA
  • Novartis AG
  • F. Hoffmann-La Roche Ltd

Data Sources and Methodology

To gather comprehensive insights on the Global Antiparasitic drugs Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.

We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Antiparasitic drugs Market.

The most resonating, simple, genuine, and important causes because of which you must decide to buy the Antiparasitic drugs market report exclusively from precedence research

  • The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2024 to 2033.

Key Features of the Report:

  • Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
  • Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
  • Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.

Market Segmentation:

By Drug Type

  • Anthelmintic
  • Antiprotozoal

By Route of Administration

  • Oral
  • Injectable
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Reasons to Consider Purchasing the Report:

  • Enhance your market research capabilities by accessing this comprehensive and precise report on the global Antiparasitic drugs market.
  • Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
  • Benefit from in-depth research and analysis of the latest trends shaping the global Antiparasitic drugs market.
  • Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Antiparasitic drugs market.
  • Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
  • Discover not only the cutting-edge technological advancements in the global Antiparasitic drugs market but also the strategic plans of industry leaders.

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antiparasitic Drug Market 

5.1. COVID-19 Landscape: Antiparasitic Drug Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antiparasitic Drug Market, By Drug Type

8.1. Antiparasitic Drug Market Revenue and Volume, by Drug Type, 2024-2033

8.1.1 Anthelmintic

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Antiprotozoal

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Antiparasitic Drug Market, By Route of Administration

9.1. Antiparasitic Drug Market Revenue and Volume, by Route of Administration, 2024-2033

9.1.1. Oral

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Injectable

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Topical

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Antiparasitic Drug Market, By Distribution Channel 

10.1. Antiparasitic Drug Market Revenue and Volume, by Distribution Channel, 2024-2033

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Antiparasitic Drug Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

Chapter 12. Company Profiles

12.1. GlaxoSmithKline plc

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Merck KGaA

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Novartis AG

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. F. Hoffmann-La Roche Ltd

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

Precedence Statistics – Empowering Your Data Insights

Contact Us

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *